The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant potential in clinical trials for managing obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a greater substantial reduction in body mass and benefit metabolic markers, part